| 规格: | 98% |
| 分子量: | 1281.85 |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
Background:
Pelcitoclax (APG-1252) is a potent Bcl-2/Bcl-xl inhibitor with antineoplastic and pro-apoptotic effects[1].
APG-1252 changes to the reactive metabolite named APG-1252-M1, which has remarkable antitumor effects in acute myeloid leukemia[1].
Pelcitoclax (APG-1252; 25-100 mg/kg; i.v.; once a day; for 10days) treatment inhibits xenograft tumor growth more obviously than the other groups[1].
[1]. Hanjie Yi, et al. Bcl-2/Bcl-xl inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma. Cancer Med. 2020 Jun;9(12):4197-4206.
m.cnreagent.com